<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-5173-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ORYVA 10MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ARIPIPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gensenta &#x130;la&#xE7; Sanayi ve Ticaret A.&#x15E;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gensenta İlaç Sanayi ve Ticaret A.Ş
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GENSENTA İLAÇ SANAYI VE TICARET A.Ş
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX12 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ORYVA contains the active substance aripiprazole and belong to a group of medicines called antipsychotics. It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness. People with this condition may also feel depressed, guilty, anxious or tense.</p><p>ORYVA is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling &quot;high&quot;, having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability. In adults it also prevents this condition from returning in patients who have responded to the treatment with ORYVA.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not take ORYVA</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to aripiprazole or any of the other ingredients of this medicine (listed in section 7).</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with ORYVA</strong></p><p>&nbsp;</p><p>Talk to your doctor before taking ORYVA.</p><p>Before treatment with ORYVA, tell your doctor if you suffer from</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar (characterised by symptoms such as excessive thirst, passing of large amounts of urine, increase in appetite and feeling weak) or family history of diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (seizures) since your doctor may want to monitor you more closely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary, irregular muscle movements, especially in the face</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular disease, stroke or &quot;mini&quot; stroke, abnormal blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots, or family history of blood clots, as antipsychotics have been associated with formation of blood clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; past experience with excessive gambling</p><p>If you notice you are gaining weight, develop unusual movements, experience somnolence that interferes with normal daily activities, any difficulty in swallowing or allergic symptoms, please tell your doctor.</p><p>If you are an elderly patient suffering from dementia (loss of memory and other mental abilities), you or your carer/relative should tell your doctor if you have ever had a stroke or &quot;mini&quot; stroke.</p><p>Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself. Suicidal thoughts and behaviours have been reported during aripiprazole treatment.</p><p>Tell your doctor immediately if you suffer from muscle stiffness or inflexibility with high fever,sweating, altered mental status, or very rapid or irregular heartbeat.</p><p>Tell your doctor if you or your family/carer notices that you are developing urges or cravings to behave in ways that are unusual for you and you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These are called impulse control disorders and can include behaviours such as addictive gambling, excessive eating or spending, an abnormally high sex drive or preoccupation with an increase in sexual thoughts or feelings.</p><p><u>Your doctor may need to adjust or stop your dose.</u></p><p><strong>Children and adolescents</strong></p><p>Do not use this medicine in children and adolescents under 13 years of age. It is not known if it is safe and effective in these patients.</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking/using other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>Blood pressure-lowering medicines: ORYVA may increase the effect of medicines used to lower the blood pressure. Be sure to tell your doctor if you take a medicine to keep your blood pressure under control.</p><p>Taking ORYVA with some medicines may mean the doctor will need to change your dose of ORYVA or the other medicines. It is especially important to mention the following to your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to correct heart rhythm (such as quinidine, amiodarone, flecainide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antidepressants or herbal remedy used to treat depression and anxiety (such as fluoxetine, paroxetine, venlafaxine, St. John&#39;s Wort)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antifungal medicines (such as ketoconazole, itraconazole)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticonvulsants used to treat epilepsy (such as carbamazepine, phenytoin, phenobarbital)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain antibiotics used to treat tuberculosis (rifabutin, rifampicin)</p><p>These medicines may increase the risk of side effects or reduce the effect of ORYVA; if you get any unusual symptom taking any of these medicines together with ORYVA you should see your doctor.</p><p>Medicines that increase the level of serotonin are typically used in conditions including depression, generalised anxiety disorder, obsessive-compulsive disorder (OCD) and social phobia as well as migraine and pain:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans, tramadol and tryptophan used for conditions including depression, generalised anxiety disorder, obsessive compulsive disorder (OCD) and social phobia as well as migraine and pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SSRI s (such as paroxetine and fluoxetine) used for depression, OCD, panic and anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other anti-depressants (such as venlafaxine and tryptophan) used in major depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tricyclic&rsquo;s (such as clomipramine and amitriptyline) used for depressive illness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s Wort (<em>Hypericum perforatum</em>) used as a herbal remedy for mild depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain killers (such as tramadol and pethidine) used for pain relief</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triptans (such as sumatriptan and zolmitripitan) used for treating migraine</p><p>These medicines may increase the risk of side effects; if you get any unusual symptom taking any of these medicines together with ORYVA, you should see your doctor.</p><p>&nbsp;</p><p><em>Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription.</em></p><p><strong>&nbsp;</strong></p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Taking ORYVA with food and drink</strong></p><p>ORYVA can be taken regardless of meals.</p><p>Alcohol should be avoided.</p><p><strong>&nbsp;</strong></p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy</strong><strong> &amp; Breastfeeding</strong></p><p><u>Pregnancy </u></p><p><em>Consult your doctor or pharmacist before taking this medicine</em></p><p><u>&nbsp;</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>The following symptoms may occur in newborn babies, of mothers that have used ORYVA in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p><em>During your treatment, if you realize that you&rsquo;re pregnant, consult your doctor or pharmacist immediately.</em></p><p><u>Breast-feeding</u></p><p><em>Consult your doctor or pharmacist before taking this medicine.</em></p><p><em>&nbsp;</em></p><p>If you are taking ORYVA, your doctor will discuss with you whether you should breast-feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding. You should not do both. Talk to your doctor about the best way to feed your baby if you are taking this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>Dizziness and vision problems may occur during treatment with this medicine (see section 5). This should be considered in cases where full alertness is required, e.g. when driving a car or handling machines.</p><p><strong>&nbsp;</strong></p><p><strong>g.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Important information regarding some excipients in ORYVA</strong></p><p>ORYVA contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>Always use ORYVA exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure.</em></p><p><strong>The recommended dose for adults is 15 mg once a day.</strong> However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p>Use in children and adolescents</p><p>This medicinal product may be started at a low dose with the oral solution (liquid) form.</p><p>The dose may be gradually increased to <strong>the recommended dose for adolescents of 10 mg once a day.</strong> However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.</p><p>If you have the impression that the effect of ORYVA is too strong or too weak, talk to your doctor or pharmacist.</p><p><strong>Method and route of administration</strong></p><p><strong>Try to take ORYVA at the same time each day.</strong> It does not matter whether you take it with or without food. Always take the tablet with water and swallow it whole.</p><p><strong>Even if you feel better,</strong> do not alter or discontinue the daily dose of ORYVA without first consulting your doctor.</p><p><em>If you have the impression that the effect of ORYVA is too strong or too weak, please contact your doctor or pharmacist.</em></p><p><em>&nbsp;</em></p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you use more ORYVA than you should</strong></p><p><em>If you take more ORYVA than the amount that you are required to take, consult your doctor or pharmacist.</em></p><p><em>&nbsp;</em></p><p>If you realise you have taken more ORYVA than your doctor has recommended (or if someone else has taken some of your ORYVA), contact your doctor right away. If you cannot reach your doctor, go to the nearest hospital and take the pack with you.</p><p>Patients who have taken too much aripiprazole have experienced the following symptoms:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid heartbeat, agitation/aggressiveness, problems with speech.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual movements (especially of the face or tongue) and reduced level of consciousness.</p><p>Other symptoms may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood pressure, abnormal rhythms of the heart.</p><p>Contact your doctor or hospital immediately if you experience any of the above.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take ORYVA</strong></p><p>If you miss a dose, take the missed dose as soon as you remember but do not take two doses in one day.</p><p><em>Do not take a double dose to make-up for the missed dose.</em></p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using ORYVA</strong></p><p>Do not stop your treatment just because you feel better. It is important that you carry on taking ORYVA for as long as your doctor has told you to.</p><p>&nbsp;</p><p><em>If you have any further questions on the use of this product, ask your doctor or pharmacist.</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong><strong>SERIOUS SIDE EFFECTS:</strong></p><p><strong>If you notice any of the following, tell your doctor immediately</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Increased mortality in elderly patients with dementia-related psychosis and suicidal thoughts and behaviors with antidepressant drugs</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders are at increased risk of suicididal thinking and behavior.</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Suicidal thoughts and behaviours have been reported during aripiprazole treatment. Tell your doctor immediately if you are having any thoughts or feelings about hurting yourself</p><p>&nbsp;</p><p><strong>Possible side effects:</strong></p><p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetes mellitus,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling restless and unable to keep still, difficulty sitting still,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable twitching, jerking or writhing movements, restless legs,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trembling,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light-headedness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shaking and blurred vision,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased number of or difficulty making bowel movements,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more saliva in mouth than normal,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood levels of the hormone prolactin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; too much sugar in the blood,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered or increased sexual interest,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable movements of mouth, tongue and limbs (tardive dyskinesia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle disorder causing twisting movements (dystonia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; double vision,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heartbeat,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a fall in blood pressure on standing up which causes dizziness, light-headedness or fainting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups.</p><p>The following side effects have been reported since the marketing of oral aripiprazole but the frequency for them to occur is not known:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of white blood cells,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of blood platelets,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (e.g. swelling in the mouth, tongue, face and throat, itching, hives),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; onset or worsening of diabetes, ketoacidosis (ketones in the blood and urine) or coma,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood sugar,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; not enough sodium in the blood,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite (anorexia),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thoughts of suicide, suicide attempt and suicide,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling aggressive,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agitation,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; combination of fever, muscle stiffness, faster breathing, sweating, reduced consciousness and sudden changes in blood pressure and heart rate, fainting (neuroleptic malignant syndrome),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serotonin syndrome (a reaction which may cause feelings of great happiness, drowsiness, clumsiness, restlessness, feeling of being drunk, fever, sweating or rigid muscles),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; speech disorder,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden unexplained death,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening irregular heartbeat,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slower heartbeat,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing (if you notice any of these symptoms, seek medical advice immediately),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fainting,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accidental inhalation of food with risk of pneumonia (lung infection),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spasm of the muscles around the voice box,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal discomfort,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach discomfort,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the skin and white part of eyes,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reports of abnormal liver tests values,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sensitivity to light,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; baldness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal muscle breakdown which can lead to kidney problems,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary loss of urine (incontinence),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in passing urine,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; withdrawal symptoms in newborn babies in case of exposure during pregnancy,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prolonged and/or painful erection,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty controlling core body temperature or overheating,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of hands, ankles or feet,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in blood tests: increased or fluctuating blood sugar, increased glycosylated haemoglobin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inability to resist the impulse, drive or temptation to perform an action that could be harmful to you or others, which may include:</p><p>o&nbsp;&nbsp; strong impulse to gamble excessively despite serious personal or family consequences</p><p>o&nbsp;&nbsp; altered or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive</p><p>o&nbsp;&nbsp; uncontrollable excessive shopping</p><p>o&nbsp;&nbsp; binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger)</p><p>o&nbsp;&nbsp; a tendency to wander away.</p><p>Tell your doctor if you experience any of these behaviours; he/she will discuss ways of managing or reducing the symptoms.</p><p>In elderly patients with dementia, more fatal cases have been reported while taking aripiprazole. In addition, cases of stroke or &quot;mini&quot; stroke have been reported.</p><p><strong>Additional side effects in children and adolescents</strong></p><p>Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (greater than 1 in 100 patients).</p><p>&nbsp;</p><p><em>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Store at room temperature below 30&deg;C and in its original package.</p><p><strong>Use in accordance with the expiration date.</strong></p><p>Do not use ORYVA after the expiration date which is stated on the blister and box. The expiry date refers to the last day of that month.</p><p>Do not use ORYVA if you notice any defect in the product and/or on the packaging.</p><p><em>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Active substance: </em></strong>Each tablet consists of 10 mg of aripiprazole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Excipients:</em></strong> Lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, red iron oxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ORYVA is in the form of light pink, oblong, flat tablets and it is supplied as 28 tablets in the form of blister packages. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>MN Pharmaceuticals</p><p>Prof. Dr. B&uuml;lent Tarcan Sok., Pak İş Merkezi No: 5/1</p><p>34349 Gayrettepe &ndash; Istanbul/TURKEY</p><p>Tel : +90.212.337 38 00</p><p>Fax : +90.212.337 38 01</p><p>e-mail : info@mn.com.tr</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer</strong></p><p>MN Pharmaceuticals</p><p>Sanayi Cad. No: 13</p><p>Yenibosna, Bah&ccedil;elievler &ndash; Istanbul/TURKEY</p><p>Tel:&nbsp;+90 212 454 76 00</p><p>Fax:&nbsp;+90 212 454 76 96</p><p>e-mail: info@mn.com.tr</p><p>&nbsp;</p><p><em>For any information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:</em></p><p><em>&nbsp;</em></p><p>Kingdom of Saudi Arabia</p><p>Salehiya Trading Establishment</p><p>P.O. Box: 991 Riyadh: 11421</p><p>Tel. No.: +966 11 464 6955</p><p>Fax No.: +966 11 463 4362</p><p>Website: www.salehiya.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 05/2019; version number 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أوريفا على المادة الفعالة أريبيبرازول و ينتمي إلى مجموعة أدوية تسمى مضادات الذهان. يستخدم لعلاج البالغين و المراهقين التي تتراوح أعمارهم من 15 سنة فما فوق الذين يعانون من مرض يتميز بأعراض مثل سمع، رؤية أو احساس أشياء غير موجودة، ارتياب، معتقدات مغلوطة، كلام وسلوك لامترابط، والتسطح العاطفي. الأشخاص في هذه الحالة قد يشعرون أيضا بالاكتئاب، بالذنب، بالقلق أو التوتر.</p><p dir="RTL">يستخدم أوريفا لعلاج البالغين و المراهقين التي تتراوح أعمارهم 13 سنة فما فوق الذين يعانون من حالة ذات أعراض مثل الشعور &quot;بالنشوة&quot;، وجود كميات زائدة من الطاقة، الحاجة إلى نوم أقل من المعتاد، التحدث بشكل سريع جداً مع افكار متسارعة و أحيانا التهيج الشديد. يستخدم أيضا لمنع هذه الحالة من العودة لدى المرضى البالغين الذين تجاوبوا مع العلاج بأوريفا.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. لا تأخذ أوريفا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كانت لديك حساسية اتجاه أريبيبرازول او اي من المكونات الأخرى لهذا الدواء (مذكورة في البند 7).</p><p dir="RTL"><strong>ب. &zwnj;تعامل مع أوريفا بعناية خاصة</strong></p><p dir="RTL">تحدث مع طبيبك قبل أن تأخذ أوريفا.</p><p dir="RTL">قبل العلاج باستخدام أوريفا، اعلم طبيبك إذا عانيت من</p><ul><li dir="RTL">ارتفاع سكر الدم (يتميز بأعراض مثل العطش المفرط، اخراج كميات كبيرة من البول، زيادة الشهية والشعور بالضعف) أو تاريخ عائلي بمرض السكري</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (تشنجات) حيث قد يود طبيبك بمراقبتك عن كثب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحركات عضلية لاإرادية غير منتظمة، خاصة في الوجه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض القلب والأوعية الدموية (أمراض القلب والدورة الدموية)، تاريخ عائلي بأمراض القلب والشرايين، سكتة دماغية أو سكتة دماغية &quot;مصغرة&quot;، ضغط الدم غير الطبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلطات الدم، أو تاريخ عائلي من الجلطات الدموية، حيث ارتبطت مضادات الذهان مع تكوين جلطات دموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجربة سابقة مع المقامرة المفرطة</p><p dir="RTL">إذا لاحظت أنك تكتسب وزناً زائداً، تحس بالنعاس بحيث يتعارض مع الأنشطة اليومية العادية، أي صعوبة في البلع أو أعراض الحساسية، يرجى اعلام طبيبك.</p><p dir="RTL">إذا كنت مريض متقدم في السن و تعاني من الخرف (فقدان الذاكرة والقدرات العقلية الأخرى)، يجب عليك أو من يقوم برعايتك / اقربائك باعلام طبيبك إذا كنت تعرضت في أي وقت مضى لسكتة دماغية أو لسكتة دماغية &quot;مصغرة&quot;.</p><p dir="RTL">اعلم طبيبك فورا إذا كانت تراودك أي أفكار أو مشاعر لأذية نفسك. قد تم الابلاغ عن أفكار و سلوكيات انتحارية خلال العلاج باستخدام أريبيبرازول.</p><p dir="RTL">اعلم طبيبك فورا إذا كنت تعاني من تصلب أو عدم مرونة في العضلات مع ارتفاع في درجة الحرارة، التعرق، تغير في الحالة النفسية، أو تسارع شديد أو عدم انتظام في ضربات القلب.</p><p dir="RTL">اعلم طبيبك إذا لاحظت أنت أو عائلتك/ مقدم الرعاية انه يتولّد لديك حوافز أو الرغبة الشديدة في التصرف بطرق غير معتادة بالنسبة لك وأنك لا تستطيع مقاومة الدافع أو الرغبة أو الإغراء للقيام بأنشطة معينة و التي من الممكن أن تسبب الأذى لك أو للآخرين. وتسمى هذه باضطرابات مكافحة التدفع ويمكن أن تشمل السلوكيات مثل المقامرة الإدمانية، الأكل أو الإنفاق المفرط، الدافع الجنسي المرتفع الغير عادي أو الانشغال بزيادة الأفكار أو المشاعر الجنسية.</p><p dir="RTL"><u>قد يضطر طبيبك إلى تعديل أو إيقاف جرعتك.</u></p><p dir="RTL"><strong>الأطفال و المراهقين</strong></p><p dir="RTL">لا تستخدم هذا الدواء مع الأطفال والمراهقين الذين تقل أعمارهم عن 13 سنة. من غير المعروف ما إذا كانت آمنة وفعالة في هؤلاء المرضى.</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخذ/استخدام أدوية أخرى</strong></p><p dir="RTL">اخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو أخذت مؤخرا أو قد تأخذ أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p dir="RTL">أدوية لخفص ضغط الدم: قد يزيد أوريفا من تأثير الأدوية المستخدمة لخفض ضغط الدم. تأكد من إخبار طبيبك إذا كنت تأخذ دواء للحفاظ على ضغط الدم تحت السيطرة.</p><p dir="RTL">تناول أوريفا مع بعض الأدوية قد يعني أن يحتاج &nbsp;طبيبك إلى تغيير جرعتك من أوريفا أو الأدوية الأخرى. من المهم جداً أن تذكر ما يلي الى طبيبك:</p><ul><li dir="RTL">أدوية لتصحيح النظم القلبي (مثل كوينيدين، أميودارون، فليكاينايد)</li><li dir="RTL">مضادات الاكتئاب أو العلاج العشبي المستخدم لعلاج الاكتئاب والقلق (مثل فلوكسيتين، باروكسيتين، فينلافاكسين، نبتة سانت جونز)</li><li dir="RTL">مضادات الفطريات (مثل كيتوكونازول، ايتراكونازول)</li><li dir="RTL">أدوية معينة لعلاج عدوى فيروس نقص المناعة البشري (مثل ايفافيرينز، نيفيرابين، مثبط البروتياز مثل ايندينافير، ريتونافير)</li><li dir="RTL">مضادات الاختلاج المستخدمة في علاج الصرع (مثل كاربامازيبين، فينيتوين، فينوباربيتال)</li><li dir="RTL">مضادات حيوية معينة تستخدم لعلاج السل (ريفابيوتين، ريفامبيسين)</li></ul><p dir="RTL">قد تزيد هذه الأدوية من مخاطر الأعراض الجانبية أو تقلل من تأثير أوريفا؛ إذا حصلت على أي أعراض غير اعتيادية عند تناول أي من هذه الأدوية بالتزامن مع أوريفا فينبغي عليك رؤية طبيبك.</p><p dir="RTL">تستخدم الأدوية التي تزيد من مستوى السيروتونين في الحالات والتي تشمل الاكتئاب، اضطراب القلق العام، اضطراب الوسواس القهري (OCD) والفوبيا الاجتماعية وكذلك الصداع النصفي والألم:</p><ul><li dir="RTL">يستخدم تريبتانات، ترامادول وتريبتوفان للحالات التي تشمل الاكتئاب، اضطراب القلق العام، اضطراب الوسواس القهري (OCD) والفوبيا الاجتماعية وكذلك الصداع النصفي والألم</li><li dir="RTL">تستخدم مثبطات استرداد السيروتونين الانتقائي (SSRI) (مثل باروكسيتين و فلوكسيتين) للاكتئاب، اضطراب الوسواس القهري (OCD)، الهلع و القلق</li><li dir="RTL">مضادات الاكتئاب الأخرى (مثل فينلافاكسين وتريبتوفان) التي تستخدم في الاكتئاب الكبير</li><li dir="RTL">مضادات الاكتئاب الثلاثية الحلقات (مثل كلوميبرامين وأميتريبتيلين) التي تستخدم في مرض الاكتئاب</li><li dir="RTL">نبتة سانت جونز (<em>Hypericum perforatum</em>) التي تستخدم كعلاج نباتي للاكتئاب الخفيف</li><li dir="RTL">مسكنات الألم (مثل ترامادول وبيثيدين) التي تستخدم لتخفيف الألم</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريبتانات (مثل سوماتريبتان وزولميتريبتان) التي تستخدم لعلاج الصداع النصفي</p><p dir="RTL">قد تزيد هذه الأدوية من مخاطر الأعراض الجانبية ؛ إذا حصلت على أي أعراض غير اعتيادية عند تناول أي من هذه الأدوية بالتزامن مع أوريفا فينبغي عليك رؤية طبيبك.</p><p dir="RTL"><em>يرجى اعلام طبيبك أو الصيدلي في حال كنت تأخذ أو أخذت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</em></p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخذ أوريفا مع الطعام أو الشراب</strong></p><p dir="RTL">يمكن تناول أوريفا مع عدم مراعاة وجبات الطعام.</p><p dir="RTL">ينبغي تجنب الكحول.</p><p dir="RTL"><strong>&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمل والرضاعة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL"><em>استشيري طبيبك أو الصيدلي قبل اخذ هذا الدواء</em></p><p dir="RTL">إذا كنت حاملا أو ترضعين، تعتقدين أنك قد تكونين حاملا أو تنوين الحمل، استشيري طبيبك قبل أخذ هذا الدواء.</p><p dir="RTL">قد تحدث الأعراض التالية لدى الأطفال حديثي الولادة لأمهات أخذن أوريفا في الأشهر الثلاثة الأخيرة من الحمل: ارتعاش، تصلب العضلات و/أو الضعف ، النعاس ، التهيج ، مشاكل في التنفس، وصعوبة في التغذية. إذا ظهر لدى طفلك أي من هذه الأعراض، فقد تحتاجين الاتصال بطبيبك.</p><p dir="RTL"><em>خلال فترة العلاج، اذا علمت أنك حامل، استشيري طبيبك او الصيدلي فوراً.</em></p><p dir="RTL"><u>الرضاعة</u></p><p dir="RTL"><em>استشيري طبيبك أو الصيدلي قبل أخذ هذا الدواء.</em></p><p dir="RTL">إذا كنت تأخذين أوريفا، فسوف يناقش طبيبك معك ما إذا كان يجب عليك الإرضاع مع الأخذ بعين الاعتبار فائدة العلاج لك وفائدة الرضاعة لطفلك. يجب عدم القيام بالاثنين معا. تحدثي إلى طبيبك حول أفضل طريقة لإطعام طفلك إذا كنت تأخذين هذا الدواء.</p><p dir="RTL"><strong>&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يحدث الشعور بالدوار و مشاكل في النظر خلال العلاج بهذا الدواء (انظر البند 5). يجب مراعاة ذلك في الحالات التي تستلزم فيها التأهب الكامل، مثلا عند قيادة السيارة أو استخدام الآلات.</p><p dir="RTL"><strong>&zwnj;ز.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معلومات مهمة بشأن بعض السواغات في أوريفا</strong></p><p dir="RTL">يحتوي أوريفا على لاكتوز. إذا قام طبيبك باعلامك أن لديك عدم تحمل لبعض السكريات، فتواصل مع طبيبك قبل أخذ هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>يجب استخدم أوريفا دائماً كما اخبرك طبيبك أو مقدم الرعاية الصحية تماماً. يجب مراجعة طبيبك، مقدم الرعاية الصحية أو الصيدلي إن كنت غير متأكد.</em></p><p dir="RTL"><strong>الجرعة المعتادة للبالغين هي 15 ملغم مرة واحدة يوميا</strong><strong>.</strong><strong> </strong>ومع ذلك، قد يصف طبيبك جرعة أقل أو أعلى بحد أقصى 30 ملغم مرة واحدة يوميا.</p><p dir="RTL">الاستخدام في الاطفال و المراهقين</p><p dir="RTL">من الممكن البدأ باستخدام هذا الدواء بجرعة منخفضة من المحلول الفموي (السائل).</p><p dir="RTL">من الممكن زيادة الجرعة تدريجيا إلى <strong>الجرعة الموصى بها للمراهقين وهي 10 ملغم مرة واحدة يوميا.</strong> ولكن قد يصف لك طبيبك جرعة أقل أو أعلى بحد أقصى 30 ملغم مرة واحدة يوميا.</p><p dir="RTL">إذا كان عندك الانطباع ان تأثير أوريفا قوي جداً أو ضعيف جداً، يرجى التحدث مه طبيبك او الصيدلي.</p><p dir="RTL"><strong>طريق الاستخدام و كيفيته</strong></p><p dir="RTL"><strong>حاول أخذ أوريفا في نفس الوقت كل يوم. </strong>من غير المهم إن أخذته مع أو بدون الطعام. خذ القرص دائماً مع الماء و قم ببلعه كاملاً.</p><p dir="RTL"><strong>حتى إن كنت تشعر بتحسن، </strong>لا تغير أو توقف الجرعة اليومية من أوريفا دون استشارة طبيبك أولا.</p><p dir="RTL"><em>إذا كان عندك الانطباع ان تأثير أوريفا قوي جداً أو ضعيف جداً، يرجى الاتصال بطبيبك او الصيدلي.</em></p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخذت أوريفا أكثر من اللازم</strong></p><p dir="RTL"><em>إذا أخذت أوريفا أكثر من الكمية التي يتعين عليك أخذها، استشر طبيبك أو الصيدلي.</em></p><p dir="RTL">إذا ادركت أنك أخذت أوريفا أكثر مما أوصى به طبيبك (أو أخذ شخص اخر القليل من أوريفا الخاص بك)، اتصل بطبيبك على الفور. إن لم تتمكن من التواصل مع طبيبك، توجه إلى أقرب مستشفى وخذ العلبة معك.</p><p dir="RTL">تعرض المرضى الذين أخذوا أريبيبرازول أكثر من اللازم للأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات قلب متسارعة، تهيج/عدوانية، مشاكل في التكلم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير اعتيادية (خاصة في الوجه أو اللسان) وانخفاض مستوى الوعي.</p><p dir="RTL">الأعراض الأخرى قد تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك الحاد، نوبات (الصرع)، الغيبوبة، مزيج من الحمى، تسارع في التنفس، التعرق،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات، والدوخة أو النعاس، تباطؤ في التنفس، الاختناق، ارتفاع أو انخفاض ضغط الدم، نظم قلبي غير اعتيادي.</p><p dir="RTL">اتصل مع طبيبك أو المستشفى فوراً إن تعرضت لأي من أعلاه.</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسيت ان تستخدم أوريفا:</strong></p><p dir="RTL">إذا كنت قد نسيت جرعة، تناول الجرعة التي نسيتها في اللحظة التي تتذكرها ولكن لا تأخذ جرعتين في يوم واحد.</p><p dir="RTL"><em>لا تأخذ جرعة مضاعفة لتعويض الجرعة التي فاتتك.</em></p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قمت بإيقاف استخدام أوريفا:</strong></p><p dir="RTL">لا توقف علاجك لمجرد شعورك بالتحسن. من الضروري متابعة أخذ أوريفا لكامل الفترة التي أخبرك عنها طبيبك.</p><p dir="RTL"><em>إذا كان لديك أي أسئلة إضافية حول استخدام هذا المنتج، فاسأل طبيبك أو الصيدلي.</em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أعراض جانبية خطيرة:</strong></p><p dir="RTL"><strong>إذا لاحظت أي من الآتي، اعلم طبيبك فوراً</strong></p><p dir="RTL"><strong>زيادة معدل الوفيات لدى المرضى المسنين المصابين بالذهان المرتبط بالخرف والأفكار والسلوكيات الانتحارية المرتبطة بالأدوية المضادة للاكتئاب</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتعرض المرضى المسنون المصابون بالذهان المرتبط بالخرف الذين يتم علاجهم بالأدوية المضادة للذهان لزيادة العرضة لخطر الموت. لم يتم الموافقة على استخدام أريبيبرازول لعلاج المرضى الذين يعانون من الذهان المرتبط بالخرف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال والمراهقون والشباب الذين يتناولون مضادات الاكتئاب من أجل الاضطراب الاكتئابي (MDD) والاضطرابات النفسية الأخرى هم أكثر عرضة لخطر التفكير والسلوك الانتحاري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم الإبلاغ عن أفكار وسلوكيات انتحارية خلال العلاج بأريبيبرازول. اعلم طبيبك فوراً إن كان لديك أي أفكار أو مشاعر حول إيذاء نفسك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية المحتملة:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">كجميع الادوية، قد يسبب هذا الدواء أعراض جانبية على الرغم من أنها قد لا تحدث مع الجميع.</p><p dir="RTL">أعراض جانبية شائعة (قد تؤثر على ما يصل إلى 1 في 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوتر،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتململ وعدم القدرة على البقاء هادئ، صعوبة في البقاء جالسا،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات ارتعاش، اهتزاز أو تلوي لا يمكن السيطرة عليها، تململ الساقين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتجاف،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اهتزاز أو تضبب الرؤية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد مرات أو صعوبة التبرز،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوعك،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كمية لعاب في الفم أكثر من المعتاد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب،</p><p dir="RTL">أعراض جانبية غير شائعة (قد تؤثر على ما يصل إلى 1 في 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستويات هرمون برولاكتن في الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كمية سكر مرتفعة جداً في الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير أو زيادة الاهتمام الجنسي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا يمكن السيطرة عليها في الفم، اللسان و الأطراف (خلل الحركة المتاخر)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب في العضلات يتسبب بحركات التوائية (خلل التوتر العضلي)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ازدواجية في النظر،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبضات قلب متسارعة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط في ضغط الدم عند الوقوف مما يؤدي الى الدوار، الدوخة أو الاغماء،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحازوقة،</p><p dir="RTL">تم الابلاغ عن الاعراض الجانبية التالية منذ بدء التسويق لأريبيبرازول الفموي لكن تكرارها غير معروف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة من كريات الدم البيضاء،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات منخفضة من الصفائح الدموية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية (مثل تورم في الفم، اللسان، الوجه و الحلق، حكة، الشرى)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أو تفاقم داء السكري، حماض كيتوني (كيتونات في الدم و البول) أو الغيبوبة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع سكر الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كمية غير كافية من الصوديوم في الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية (قهم)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افكار انتحارية، محاولة الانتحار و الانتحار،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعدوانية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عصبية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزيج من الحمى، تصلب العضلات، تسارع في التنفس، تعرق، تدني الوعي وتغيرات مفاجئة في ضغط الدم ومعدل ضربات القلب، الاغماء (المتلازمة الخبيثة للدواء المضاد للذهان)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة تشنجية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة السيروتونين (رد فعل قد يسبب مشاعر سعادة عارمة، نعاس، الخرق، تململ، الشعور بالثمل، حمى، تعرق أو تصلب العضلات)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل في التكلم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت مفاجئ غير مبرر،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير منتظمة والتي تهدد الحياة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تباطؤ نبضات القلب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجلطات الدم في الأوردة خاصة في الساقين (أعراض تتضمن التورم، ألم واحمرار في الساق)، والتي قد تنتقل عبر الأوعية الدموية إلى الرئتين مسببة ألم في الصدر وصعوبة في التنفس (إذا لاحظت أي من هذه الأعراض، اطلب الاعانة الطبية على الفور)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغماء،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استنشاق عرضي للطعام مع خطر الالتهاب الرئوي (التهاب الرئة)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلص العضلات المحيطة بحنجرة الصوت،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اسهال،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الارتياح في البطن،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بعدم الارتياح في المعدة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل كبدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الكبد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد و الجزء الابيض من العيون،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقارير بقيم غير طبيعية لاختبارات الكبد،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حساسية تجاه الضوء،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصلع،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق مفرط،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدهور عضلي غير طبيعي والذي من الممكن أن يؤدي الى مشاكل في الكلى،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلّب،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان بول غير طوعي (سلس البول)،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض انسحابية في الاطفال حديثي الولادة في حالات التعرض خلال الحمل،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب مطوّل أو مؤلم،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في السيطرة على درجة حرارة الجسم الباطنية أو ارتفاع مفرط في درجة الحرارة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في اليدين، الكاحلين أو القدمين،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في تحاليل الدم: زيادة أو تذبذب السكر في الدم، زيادة في الهيموغلوبين الغليكوزيلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على مقاومة الدافع، الرغبة أو الإغراء لفعل عمل من الممكن ان يؤذيك او يؤذي الاخرين، ويتضمن:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دافع قوي للمقامرة بشكل مفرط بالرغم من عواقب شخصية او عائلية وخيمة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير او زيادة في الاهتمام و التصرف الجنسي اللذين يشكلان مصدر قلق كبير لك و للاخرين، على سبيل المثال، زيادة في الرغبة الجنسية</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسوق مفرط غير مسيطر عليه</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكل بشراهة (اكل كميات كبيرة من الطعام في فترة قصيرة من الوقت) او الاكل القهري (اكل كميات الطعام اكثر من المعتاد او اكثر من المطلوب لسد جوعك)</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميل للتجول بعيدا.</p><p dir="RTL">اعلم طبيبك ان واجهت اي من هذه السلوكيات، حيث سيقوم بمناقشة سبل تدبير او تقليل الاعراض.</p><p dir="RTL">تم الإبلاغ أكثر عن حالات مميتة أثناء تناول أريبيبرازول في المرضى المسنين المصابين بالخرف. وبالإضافة إلى ذلك، تم الإبلاغ عن حالات سكتة دماغية أو سكتة دماغية &quot;مصغرة&quot;.</p><p dir="RTL"><strong>اعراض جانبية اضافية في الاطفال و المراهقين</strong></p><p dir="RTL">تعرض المراهقين الذين تتراوح اعمارهم 13 سنة فما فوق لاعراض جانبية مماثلة في التردد والنوع للبالغين باستثناء النعاس، حركات ارتعاش أو اهتزاز لا يمكن السيطرة عليها، تململ و التعب كانت شائعة جدا (اكثر من 1 في 10 مرضى) و الم في منطقة البطن العلوي، جفاف الفم، زيادة معدل ضربات القلب، زيادة الوزن، زيادة الشهية، رعشة العضلات، حركات لاإرادية في الأطراف، و الشعور بالدوار خصوصا عند القيام من وضعية التمدد أو الجلوس كانت شائعة (اكثر من 1 في 100 مريض).</p><p dir="RTL"><em>إذا أصبحت إحدى الأعراض الجانبية خطيرة، أو إذا لاحظت أي أعراض جانبية غير مذكورة في النشرة، يرجى اعلام طبيبك، مقدم الرعاية الصحية أو الصيدلي.</em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول و مرأى الأطفال.</p><p dir="RTL">يحفظ في درجة حرارة الغرفة، دون 30&deg; م، ويحفظ في علبته الأصلية.</p><p dir="RTL"><strong>يستخدم وفقاً لتاريخ الانتهاء.</strong></p><p dir="RTL">لا تستخدم أوريفا بعد تاريخ الانتهاء المذكور على الشريط والعلبة. يعود تاريخ الانتهاء إلى آخر يوم في الشهر.</p><p dir="RTL">لا تستخدم أوريفا إذا لاحظت أي عيب في المنتج و/أو علبته.</p><p dir="RTL"><em>لا ينبغي أن يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجتها. من شأن هذه التدابير أن تساعد على حماية البيئة.</em></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>المادة الفعالة</em></strong><strong>: </strong>يحتوي كل قرص على 10 ملغم أريبيبرازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>المسوغات</em></strong><em>: </em>مونوهيدرات اللاكتوز، نشا الذرة، السليلوز ذو التبلور الدقيق ، هايدروكسي بروبيل السليلوز ، ستيرات المغنيسيوم، وأكسيد الحديد الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong><em>ب.&nbsp; &nbsp; &nbsp; &nbsp;</em></strong><strong><em>كيف يبدو أوريفا وماهي محتويات العلبة:</em></strong></p><p dir="RTL">يكون أوريفا على شكل أقراص بلون وردي فاتح، مستطيلة مسطحة، و متوفرة بعدد 28 قرص على شكل أشرطة مغلفة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">إم إن للمستحضرات الصيدلانية</p><p dir="RTL">Prof. Dr. B&uuml;lent Tarcan Sok.، Pak İş Merkezi No: 5/1</p><p>34349 Gayrettepe</p><p>اسطنبول / تركيا</p><p dir="RTL">تليفون:<strong> </strong>+90.212.337 38 00</p><p dir="RTL">فاكس:<strong> </strong>+90.212.337 38 01</p><p dir="RTL">بريد الكتروني: info@mn.com.tr</p><p dir="RTL"><strong>المصنّع:</strong></p><p dir="RTL">إم إن للمستحضرات الصيدلانية</p><p>سانايي شارع رقم: 13</p><p dir="RTL">ينيبوسنا، باهسيليفلر &ndash; اسطنبول/ تركيا</p><p dir="RTL">تليفون: +90 212 454 76 00</p><p dir="RTL">فاكس: +90 212 454 76 96</p><p dir="RTL">بريد الكتروني: info@mn.com.tr</p><p dir="RTL"><em>لأي معلومات عن هذا المنتج الطبي، يرجى التواصل مع الوكيل المحلي لحامل ترخيص التسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">مؤسسة الصالحية التجارية</p><p dir="RTL">ص.ب. 991 الرياض 11421</p><p dir="RTL">تليفون: +966 11 464 6955</p><p dir="RTL">فاكس: +966 11 463 4362</p><p dir="RTL">موقع الكتروني: www.salehiya.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آخر تاريخ لاعتماد هذه النشرة هو 05/2019، رقم الاصدار: 03
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ORYVA 10 mg tablet 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Substance:
Aripiprazole 			10 mg
Excipients:
Lactose Monohydrate		65.72 mg
See section 6.1 for full list of excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.
Light pink colored, oblong, flat tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ORYVA is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.</p><p>ORYVA is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment (see section 5.1).</p><p>ORYVA is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adults </strong></p><p><u>&nbsp;</u></p><p><em><u>Schizophrenia:</u></em><em> </em>The recommended starting dose for ORYVA is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals. ORYVA is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 15 mg has not been demonstrated although individual patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p><em>&nbsp;</em></p><p><em><u>Manic episodes in Bipolar I Disorder:</u></em> The recommended starting dose for ORYVA is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1). Some patients may benefit from a higher dose. The maximum daily dose should not exceed 30 mg.</p><p><u>&nbsp;</u></p><p><em><u>Recurrence prevention of manic episodes in Bipolar I Disorder:</u></em><em> </em>For preventing recurrence of manic episodes in patients, who have been receiving aripiprazole as monotherapy or combination therapy, continue therapy at the same dose. Adjustments of daily dosage, including dose reduction should be considered on the basis of clinical status.</p><p><strong>&nbsp;</strong></p><p><strong>Pediatric population</strong></p><p><u>&nbsp;</u></p><p><em><u>Schizophrenia in adolescents aged 15 years and older</u></em><u>:</u> The recommended dose for ORYVA is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. When appropriate, subsequent dose increases should be administered in 5 mg increments without exceeding the maximum daily dose of 30 mg (see section 5.1). ORYVA is effective in a dose range of 10 to 30 mg/day. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated although individual patients may benefit from a higher dose.</p><p>ORYVA is not recommended for use in patients with schizophrenia below 15 years of age due to insufficient data on safety and efficacy (see sections 4.8 and 5.1).</p><p><em><u>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</u></em><u>:</u> The recommended dose for ORYVA is 10 mg/day administered on a once-a-day schedule without regard to meals. Treatment should be initiated at 2 mg for 2 days, titrated to 5 mg for 2 additional days to reach the recommended daily dose of 10 mg. The treatment duration should be the minimum necessary for symptom control and must not exceed 12 weeks. Enhanced efficacy at doses higher than a daily dose of 10 mg has not been demonstrated, and a daily dose of 30 mg is associated with a substantially higher incidence of significant adverse reactions including EPS related events, somnolence, fatigue and weight gain (see section 4.8). Doses higher than 10 mg/day should therefore only be used in exceptional cases and with close clinical monitoring (see sections 4.4, 4.8 and 5.1). Younger patients are at increased risk of experiencing adverse events associated with aripiprazole. Therefore, ORYVA is not recommended for use in patients below 13 years of age (see sections 4.8 and 5.1).</p><p><em><u>Irritability associated with autistic disorder:</u></em> the safety and efficacy of ORYVA in children and adolescents aged below 18 years have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><em><u>Tics associated with Tourette&#39;s disorder:</u></em> The safety and efficacy of ORYVA in children and adolescents 6 to 18 years of age have not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.</p><p><strong>&nbsp;</strong></p><p><strong>Method of administration</strong></p><p>ORYVA is for oral use.</p><p>ORYVA tablet is taken with enough amount of water (for example, a glass) on empty or full stomach.</p><p><strong>&nbsp;</strong></p><p><strong>Additional information for special populations</strong></p><p><strong>&nbsp;</strong></p><p><strong>Hepatic impairment</strong></p><p>No dosage adjustment is required for patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the data available are insufficient to establish recommendations. In these patients dosing should be managed cautiously. However, the maximum daily dose of 30 mg should be used with caution in patients with severe hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>No dosage adjustment is required in patients with renal impairment.</p><p><strong>&nbsp;</strong></p><p><strong>Elderly</strong></p><p>The safety and efficacy of aripiprazole in the treatment of schizophrenia or manic episodes in Bipolar I Disorder in patients aged 65 years and older has not been established. Owing to the greater sensitivity of this population, a lower starting dose should be considered when clinical factors warrant (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><strong>Gender</strong></p><p>No dosage adjustment is required for female patients as compared to male patients (see section 5.2).</p><p><strong>&nbsp;</strong></p><p><strong>Smoking status</strong></p><p>According to the metabolic pathway of aripiprazole no dosage adjustment is required for smokers (see section 4.5).</p><p>&nbsp;</p><p><strong>Dose adjustments due to interactions </strong></p><p>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, aripiprazole dose should then be increased (see section 4.5).</p><p>&nbsp;</p><p>When concomitant administration of strong CYP3A4 or CYP2D6 inhibitors with aripiprazole occurs, the aripiprazole dose should be reduced. When the CYP3A4 or CYP2D6 inhibitors is withdrawn from the combination therapy, the aripiprazole dose should then be increased (see section 4.5).</p><p>When concomitant administration of strong CYP3A4 inducers with aripiprazole occurs, the aripiprazole dose should be increased. When the CYP3A4 inducer is withdrawn from the combination therapy, the aripiprazole dose should then be reduced to the recommended dose (see section 4.5).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored throughout this period.</p><p><u>Suicidality</u></p><p>The occurrence of suicidal behaviour is inherent in psychotic illnesses and mood disorders and in some cases has been reported early after initiation or switch of antipsychotic treatment, including treatment with aripiprazole (see section 4.8). Close supervision of high-risk patients should accompany antipsychotic treatment.</p><p><u>Cardiovascular disorders</u></p><p>Aripiprazole should be used with caution in patients with known cardiovascular disease (history of myocardial infarction or ischaemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medicinal products) or hypertension, including accelerated or malignant. Cases of venous thromboembolism (VTE) have been reported with antipsychotic medicinal products. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with aripiprazole and preventive measures undertaken.</p><p><u>QT prolongation</u></p><p>In clinical trials of aripiprazole, the incidence of QT prolongation was comparable to placebo. Aripiprazole should be used with caution in patients with a family history of QT prolongation (see section 4.8).</p><p><u>Tardive dyskinesia</u></p><p>In clinical trials of one year or less duration, there were uncommon reports of treatment emergent dyskinesia during treatment with aripiprazole. If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8). These symptoms can temporally deteriorate or can even arise after discontinuation of treatment.</p><p><u>Other extrapyramidal symptoms</u></p><p>In paediatric clinical trials of aripiprazole akathisia and Parkinsonism were observed. If signs and symptoms of other EPS appear in a patient taking aripiprazole, dose reduction and close clinical monitoring should be considered.</p><p><u>Neuroleptic Malignant Syndrome (NMS)</u></p><p>NMS is a potentially fatal symptom complex associated with antipsychotics. In clinical trials, rare cases of NMS were reported during treatment with aripiprazole. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. However, elevated creatine phosphokinase and rhabdomyolysis, not necessarily in association with NMS, have also been reported. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotics, including aripiprazole, must be discontinued.</p><p>&nbsp;</p><p><u>Seizure</u></p><p>In clinical trials, uncommon cases of seizure were reported during treatment with aripiprazole. Therefore, aripiprazole should be used with caution in patients who have a history of seizure disorder or have conditions associated with seizures (see section 4.8).</p><p><u>Elderly patients with dementia-related psychosis</u></p><p><em>Increased mortality</em></p><p>In three placebo-controlled trials (n = 938; mean age: 82.4 years; range: 56-99 years) of aripiprazole in elderly patients with psychosis associated with Alzheimer&#39;s disease, patients treated with aripiprazole were at increased risk of death compared to placebo. The rate of death in aripiprazole-treated patients was 3.5 % compared to 1.7 % in the placebo group. Although the causes of deaths were varied, most of the deaths appeared to be either cardiovascular (e.g. heart failure, sudden death) or infectious (e.g. pneumonia) in nature (see section 4.8).</p><p><em>Cerebrovascular adverse reactions</em></p><p>In the same trials, cerebrovascular adverse reactions (e.g. stroke, transient ischaemic attack), including fatalities, were reported in patients (mean age: 84 years; range: 78-88 years). Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials. This difference was not statistically significant. However, in one of these trials, a fixed-dose trial, there was a significant dose response relationship for cerebrovascular adverse reactions in patients treated with aripiprazole (see section 4.8).</p><p>Aripiprazole is not indicated for the treatment of patients with dementia-related psychosis.</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>Hyperglycaemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics, including aripiprazole. Risk factors that may predispose patients to severe complications include obesity and family history of diabetes. In clinical trials with aripiprazole, there were no significant differences in the incidence rates of hyperglycaemia-related adverse reactions (including diabetes) or in abnormal glycaemia laboratory values compared to placebo. Precise risk estimates for hyperglycaemia-related adverse reactions in patients treated with aripiprazole and with other atypical antipsychotics are not available to allow direct comparisons. Patients treated with any antipsychotics, including aripiprazole, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control (see section 4.8).</p><p><u>Hypersensitivity</u></p><p>Hypersensitivity reactions, characterised by allergic symptoms, may occur with aripiprazole (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>Weight gain</u></p><p>Weight gain is commonly seen in schizophrenic and bipolar mania patients due to co-morbidities, use of antipsychotics known to cause weight gain, poorly managed life-style, and might lead to severe complications. Weight gain has been reported post-marketing among patients prescribed aripiprazole. When seen, it is usually in those with significant risk factors such as history of diabetes, thyroid disorder or pituitary adenoma. In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain in adults (see section 5.1). In clinical trials of adolescent patients with bipolar mania, aripiprazole has been shown to be associated with weight gain after 4 weeks of treatment. Weight gain should be monitored in adolescent patients with bipolar mania. If weight gain is clinically significant, dose reduction should be considered (see section 4.8).</p><p><u>Dysphagia</u></p><p>Oesophageal dysmotility and aspiration have been associated with the use of antipsychotics, including aripiprazole. Aripiprazole should be used cautiously in patients at risk for aspiration pneumonia.</p><p><u>Pathological gambling and other impulse control disorders</u></p><p>Patients can experience increased urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other urges, reported, include: increased sexual urges, compulsive shopping, binge or compulsive eating, and other impulsive and compulsive behaviours. It is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, compulsive shopping, binge or compulsive eating, or other urges while being treated with aripiprazole. It should be noted that impulse-control symptoms can be associated with the underlying disorder; however, in some cases, urges were reported to have stopped when the dose was reduced or the medication was discontinued. Impulse control disorders may result in harm to the patient and others if not recognised. Consider dose reduction or stopping the medication if a patient develops such urges while taking aripiprazole (see section 4.8).</p><p><u>Lactose</u></p><p>ORYVA tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p><u>Patients with ADHD comorbidity</u></p><p>Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its &alpha;<sub>1</sub>-adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive medicinal products.</p><p>Given the primary CNS effects of aripiprazole, caution should be used when aripiprazole is administered in combination with alcohol or other CNS medicinal products with overlapping adverse reactions such as sedation (see section 4.8).</p><p>If aripiprazole is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance, caution should be used.</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Potential for other medicinal products to affect aripiprazole</u></p><p>A gastric acid blocker, the H<sub>2</sub> antagonist famotidine, reduces aripiprazole rate of absorption but this effect is deemed not clinically relevant. Aripiprazole is metabolised by multiple pathways involving the CYP2D6 and CYP3A4 enzymes but not CYP1A enzymes. Thus, no dosage adjustment is required for smokers.</p><p><em>Quinidine and other CYP2D6 inhibitors</em></p><p>In a clinical trial in healthy subjects, a strong inhibitor of CYP2D6 (quinidine) increased aripiprazole AUC by 107 %, while C<sub>max</sub> was unchanged. The AUC and C<sub>max</sub> of dehydro-aripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively. Aripiprazole dose should be reduced to approximately one-half of its prescribed dose when concomitant administration of aripiprazole with quinidine occurs. Other strong inhibitors of CYP2D6, such as fluoxetine and paroxetine, may be expected to have similar effects and similar dose reductions should therefore be applied.</p><p><em>Ketoconazole and other CYP3A4 inhibitors</em></p><p>In a clinical trial in healthy subjects, a strong inhibitor of CYP3A4 (ketoconazole) increased aripiprazole AUC and C<sub>max</sub> by 63 % and 37 %, respectively. The AUC and C<sub>max</sub> of dehydro-aripiprazole increased by 77 % and 43 %, respectively. In CYP2D6 poor metabolisers, concomitant use of strong inhibitors of CYP3A4 may result in higher plasma concentrations of aripiprazole compared to that in CYP2D6 extensive metabolizers. When considering concomitant administration of ketoconazole or other strong CYP3A4 inhibitors with aripiprazole, potential benefits should outweigh the potential risks to the patient. When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to approximately one-half of its prescribed dose. Other strong inhibitors of CYP3A4, such as itraconazole and HIV protease inhibitors may be expected to have similar effects and similar dose reductions should therefore be applied (see section 4.2). Upon discontinuation of the CYP2D6 or CYP3A4 inhibitor, the dosage of aripiprazole should be increased to the level prior to the initiation of the concomitant therapy. When weak inhibitors of CYP3A4 (e.g. diltiazem) or CYP2D6 (e.g. escitalopram) are used concomitantly with aripiprazole, modest increases in plasma aripiprazole concentrations may be expected.</p><p><em>Carbamazepine and other CYP3A4 inducers</em></p><p>Following concomitant administration of carbamazepine, a strong inducer of CYP3A4, and oral aripiprazole to patients with schizophrenia or schizoaffective disorder, the geometric means of C<sub>max</sub> and AUC for aripiprazole were 68 % and 73 % lower, respectively, compared to when aripiprazole (30 mg) was administered alone. Similarly, for dehydro-aripiprazole the geometric means of C<sub>max</sub> and AUC after carbamazepine co-administration were 69 % and 71 % lower, respectively, than those following treatment with aripiprazole alone. Aripiprazole dose should be doubled when concomitant administration of aripiprazole occurs with carbamazepine. Concomitant administration of aripiprazole and other inducers of CYP3A4 (such as rifampicin, rifabutin, phenytoin, phenobarbital, primidone, efavirenz, nevirapine and St. John&#39;s Wort) may be expected to have similar effects and similar dose increases should therefore be applied. Upon discontinuation of strong CYP3A4 inducers, the dosage of aripiprazole should be reduced to the recommended dose.</p><p><em>Valproate and lithium</em></p><p>When either valproate or lithium was administered concomitantly with aripiprazole, there was no clinically significant change in aripiprazole concentrations and therefore no dose adjustment is necessary when either valproate or lithium is administered with aripiprazole.</p><p><u>Potential for aripiprazole to affect other medicinal products</u></p><p>In clinical studies, 10-30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan). Additionally, aripiprazole and dehydro-aripiprazole did not show potential for altering CYP1A2-mediated metabolism <em>in vitro</em>. Thus, aripiprazole is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.</p><p>When aripiprazole was administered concomitantly with either valproate, lithium or lamotrigine, there was no clinically important change in valproate, lithium or lamotrigine concentrations.</p><p>&nbsp;</p><p><em>Serotonin syndrome</em></p><p>Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as SSRI/SNRI, or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>General advice</strong></p><p>Pregnancy Category: C.</p><p><strong>Pregnancy</strong></p><p>There are no adequate and well-controlled trials of aripiprazole in pregnant women. Congenital anomalies have been reported; however, causal relationship with aripiprazole could not be established. Animal studies could not exclude potential developmental toxicity (see section 5.3). Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole. Due to insufficient safety information in humans and concerns raised by animal reproductive studies, this medicinal product should not be used in pregnancy unless the expected benefit clearly justifies the potential risk to the foetus.</p><p>Newborn infants exposed to antipsychotics (including aripiprazole) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborn infants should be monitored carefully (see section 4.8).<strong> </strong></p><p><strong>Breast-feeding </strong></p><p>Aripiprazole is excreted in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from aripiprazole therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p><strong>Fertility</strong></p><p>Aripiprazole did not impair fertility based on data from reproductive toxicity studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aripiprazole has minor to moderate influence on the ability to drive and use machines due to potential nervous system and visual effects, such as sedation, somnolence, syncope, vision blurred, diplopia (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>The most commonly reported adverse reactions in placebo-controlled trials were akathisia and nausea each occurring in more than 3 % of patients treated with oral aripiprazole.</p><p><strong>&nbsp;</strong></p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>The incidences of the Adverse Drug Reactions (ADRs) associated with aripiprazole therapy are tabulated below. The table is based on adverse events reported during clinical trials and/or post-marketing use.</p><p>All ADRs are listed by system organ class and frequency; very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia</p><p>Neutropenia</p><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction (e.g. anaphylactic reaction, angioedema including swollen tongue, tongue oedema, face oedema, pruritus, or urticaria)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperprolactinaemia</p></td><td style="vertical-align:top"><p>Diabetic hyperosmolar coma</p><p>Diabetic ketoacidosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Diabetes mellitus</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top"><p>Hyponatremia</p><p>Anorexia</p><p>Weight decreased</p><p>Weight gain</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia</p><p>Anxiety</p><p>Restlessness</p></td><td style="vertical-align:top"><p>Depression,</p><p>Hypersexuality</p></td><td style="vertical-align:top"><p>Suicide attempt, suicidal ideation and completed suicide (see section 4.4)</p><p>Pathological gambling</p><p>Impulse-control disorders</p><p>Binge eating</p><p>Compulsive shopping</p><p>Poriomania</p><p>Aggression</p><p>Agitation</p><p>Nervousness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Akathisia</p><p>Extrapyramidal disorder</p><p>Tremor</p><p>Headache</p><p>Sedation</p><p>Somnolence</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Tardive dyskinesia</p><p>Dystonia</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome (NMS)</p><p>Grand mal convulsion</p><p>Serotonin syndrome</p><p>Speech disorder</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Diplopia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Sudden unexplained death</p><p>Torsades de pointes</p><p>QT prolongation</p><p>Ventricular arrhythmias</p><p>Cardiac arrest</p><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)</p><p>Hypertension</p><p>Syncope</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hiccups</p></td><td style="vertical-align:top"><p>Aspiration pneumonia</p><p>Laryngospasm</p><p>Oropharyngeal spasm</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Constipation</p><p>Dyspepsia</p><p>Nausea</p><p>Salivary hypersecretion</p><p>Vomiting</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pancreatitis</p><p>Dysphagia</p><p>Diarrhoea</p><p>Abdominal discomfort</p><p>Stomach discomfort</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic failure</p><p>Hepatitis</p><p>Jaundice</p><p>Increased Alanine Aminotransferase (ALT)</p><p>Increased Aspartate Aminotransferase (AST)</p><p>Increased Gamma Glutamyl Transferase (GGT)</p><p>Increased alkaline phosphatase</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p><p>Photosensitivity reaction</p><p>Alopecia</p><p>Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Myalgia</p><p>Stiffness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Urinary incontinence</p><p>Urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Priapism</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Temperature regulation disorder (e.g. hypothermia, pyrexia)</p><p>Chest pain</p><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood glucose increased</p><p>Glycosylated haemoglobin increased</p><p>Blood glucose fluctuation</p><p>Increased creatine phosphokinase</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>c. Description of selected adverse reactions</strong></p><p>&nbsp;</p><p><em><u>Adults&nbsp; </u></em></p><p>&nbsp;</p><p><em>Extrapyramidal symptoms (EPS) </em></p><p>&nbsp;</p><p><em>Schizophrenia:</em> In a long term 52-week controlled trial, aripiprazole-treated patients had an overall-lower incidence (25.8 %) of EPS including Parkinsonism, akathisia, dystonia and dyskinesia compared with those treated with haloperidol (57.3 %). In a long term 26-week placebo-controlled trial, the incidence of EPS was 19 % for aripiprazole-treated patients and 13.1 % for placebo-treated patients. In another long-term 26-week controlled trial, the incidence of EPS was 14.8 % for aripiprazole-treated patients and 15.1 % for olanzapine-treated patients.</p><p>&nbsp;</p><p><em>Manic episodes in Bipolar I Disorder:</em> In a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients. In another 12-week trial, the incidence of EPS was 26.6 % for patients treated with aripiprazole and 17.6 % for those treated with lithium. In the long term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.</p><p>&nbsp;</p><p><em>Akathisia </em></p><p>&nbsp;</p><p>In placebo-controlled trials, the incidence of akathisia in bipolar patients was 12.1 % with aripiprazole and 3.2 % with placebo. In schizophrenia patients the incidence of akathisia was 6.2 % with aripiprazole and 3.0 % with placebo.</p><p>&nbsp;</p><p><em>Dystonia </em></p><p>&nbsp;</p><p>Class effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic medicinal products. An elevated risk of acute dystonia is observed in males and younger age groups.</p><p>&nbsp;</p><p><em>Prolactin </em></p><p>&nbsp;</p><p>In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).</p><p>&nbsp;</p><p><em>Laboratory parameters </em></p><p>&nbsp;</p><p>Comparisons between aripiprazole and placebo in the proportions of patients experiencing potentially clinically significant changes in routine laboratory and lipid parameters (see section 5.1) revealed no medically important differences. Elevations of CPK (Creatine Phosphokinase), generally transient and asymptomatic, were observed in 3.5 % of aripiprazole treated patients as compared to 2.0 % of patients who received placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>d. Paediatric population</strong></p><p><strong>&nbsp;</strong></p><p><em>Schizophrenia in adolescents aged 15 years and older</em></p><p>In a short-term placebo-controlled clinical trial involving 302 adolescents (13-17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):</p><p>Somnolence/sedation and extrapyramidal disorder were reported very commonly (&ge; 1/10), and dry mouth, increased appetite, and orthostatic hypotension were reported commonly (&ge; 1/100, &lt; 1/10). The safety profile in a 26-week open-label extension trial was similar to that observed in the short-term, placebo-controlled trial.</p><p>The safety profile of a long-term, double-blind placebo controlled trial was also similar except for the following reactions that were reported more frequently than paediatric patients taking placebo: weight decreased, blood insulin increased, arrhythmia, and leukopenia were reported commonly (&ge; 1/100, &lt; 1/10).</p><p>In the pooled adolescent schizophrenia population (13-17 years) with exposure up to 2 years, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 29.5 % and 48.3 %, respectively. In the adolescent (13-17 years) schizophrenia population with aripiprazole exposure of 5 to 30 mg up to 72 months, incidence of low serum prolactin levels in females (&lt;3 ng/ml) and males (&lt; 2 ng/ml) was 25.6 % and 45.0 %, respectively.</p><p>In two long term trials with adolescent (13-17 years) schizophrenia and bipolar patients treated with aripiprazole, incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) was 37.0 % and 59.4 %, respectively.</p><p><em>Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older</em></p><p>The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (&ge; 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (&ge; 1/100, &lt; 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.</p><p>The following adverse reactions had a possible dose response relationship; extrapyramidal disorder (incidences were 10 mg, 9.1 %, 30 mg, 28.8 %, placebo, 1.7 %,); and akathisia (incidences were 10 mg, 12.1 %, 30 mg, 20.3 %, placebo, 1.7 %).</p><p>Mean changes in body weight in adolescents with Bipolar I Disorder at 12 and 30 weeks for aripiprazole were 2.4 kg and 5.8 kg, and for placebo 0.2 kg and 2.3 kg, respectively.</p><p>In the paediatric population somnolence and fatigue were observed more frequently in patients with bipolar disorder compared to patients with schizophrenia.</p><p>In the paediatric bipolar population (10-17 years) with exposure up to 30 weeks, incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) was 28.0 % and 53.3 %, respectively.</p><p><em>Pathological gambling and other impulse control disorders</em></p><p>Pathological gambling, hypersexuality, compulsive shopping and binge or compulsive eating can occur in patients treated with aripiprazole (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&bull; Toll free phone: 8002490000</p><p>&bull; E-mail: npc.drug@sfda.gov.sa</p><p>&bull; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>In clinical trials and post-marketing experience, accidental or intentional acute overdose of aripiprazole alone was identified in adult patients with reported estimated doses up to 1,260 mg with no fatalities. The potentially medically important signs and symptoms observed included lethargy, increased blood pressure, somnolence, tachycardia, nausea, vomiting and diarrhoea. In addition, reports of accidental overdose with aripiprazole alone (up to 195 mg) in children have been received with no fatalities. The potentially medically serious signs and symptoms reported included somnolence, transient loss of consciousness and extrapyramidal symptoms.</p><p><u>Management of overdose</u></p><p>Management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. The possibility of multiple medicinal product involvement should be considered. Therefore cardiovascular monitoring should be started immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. Following any confirmed or suspected overdose with aripiprazole, close medical supervision and monitoring should continue until the patient recovers.</p><p>Activated charcoal (50 g), administered one hour after aripiprazole, decreased aripiprazole C<sub>max</sub> by about 41 % and AUC by about 51 %, suggesting that charcoal may be effective in the treatment of overdose.</p><p><u>Haemodialysis</u></p><p>Although there is no information on the effect of haemodialysis in treating an overdose with aripiprazole, haemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Psycholeptics, other antipsychotics</p><p>ATC code: N05AX12</p><p><u>Mechanism of action</u></p><p>It has been proposed that aripiprazole&#39;s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D<sub>2</sub> and serotonin 5-HT<sub>1A</sub> receptors and antagonism of serotonin 5-HT<sub>2A</sub> receptors. Aripiprazole exhibited antagonist properties in animal models of dopaminergic hyperactivity and agonist properties in animal models of dopaminergic hypoactivity. Aripiprazole exhibited high binding affinity <em>in vitro</em> for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors and moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2C</sub> and 5-HT<sub>7</sub>, alpha-1 adrenergic and histamine H<sub>1</sub> receptors. Aripiprazole also exhibited moderate binding affinity for the serotonin reuptake site and no appreciable affinity for muscarinic receptors. Interaction with receptors other than dopamine and serotonin subtypes may explain some of the other clinical effects of aripiprazole.</p><p>Aripiprazole doses ranging from 0.5 to 30 mg administered once a day to healthy subjects for 2 weeks produced a dose-dependent reduction in the binding of <sup>11</sup>C-raclopride, a D<sub>2</sub>/D<sub>3</sub> receptor ligand, to the caudate and putamen detected by positron emission tomography.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Adults</u></em><em> </em></p><p><em>Schizophrenia</em></p><p>In three short-term (4 to 6 weeks) placebo-controlled trials involving 1,228 schizophrenic adult patients, presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo.</p><p>Aripiprazole is effective in maintaining the clinical improvement during continuation therapy in adult patients who have shown an initial treatment response. In a haloperidol-controlled trial, the proportion of responder patients maintaining response to medicinal product at 52-weeks was similar in both groups (aripiprazole 77 % and haloperidol 73 %). The overall completion rate was significantly higher for patients on aripiprazole (43 %) than for haloperidol (30 %). Actual scores in rating scales used as secondary endpoints, including PANSS and the Montgomery-Asberg Depression Rating Scale showed a significant improvement over haloperidol.</p><p>In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, aripiprazole had significantly greater reduction in relapse rate, 34 % in aripiprazole group and 57 % in placebo.</p><p><em>Weight gain</em></p><p>In clinical trials aripiprazole has not been shown to induce clinically relevant weight gain. In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary end-point was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).</p><p><em>Lipid parameters</em></p><p>In a pooled analysis on lipid parameters from placebo controlled clinical trials in adults, aripiprazole has not been shown to induce clinically relevant alterations in levels of total cholesterol, triglycerides, HDL and LDL.</p><p><em>Prolactin</em></p><p>Prolactin levels were evaluated in all trials of all doses of aripiprazole (n = 28,242). The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %). For patients receiving aripiprazole, the median time to onset was 42 days and median duration was 34 days.</p><p>The incidence of hypoprolactinaemia or decreased serum prolactin in patients treated with aripiprazole was 0.4 %, compared with 0.02 % for patients treated with placebo. For patients receiving aripiprazole, the median time to onset was 30 days and median duration was 194 days.</p><p><em>Manic episodes in Bipolar I Disorder</em></p><p>In two 3-week, flexible-dose, placebo-controlled monotherapy trials involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole demonstrated superior efficacy to placebo in reduction of manic symptoms over 3 weeks. These trials included patients with or without psychotic features and with or without a rapid-cycling course.</p><p>In one 3-week, fixed-dose, placebo-controlled monotherapy trial involving patients with a manic or mixed episode of Bipolar I Disorder, aripiprazole failed to demonstrate superior efficacy to placebo.</p><p>In two 12-week, placebo- and active-controlled monotherapy trials in patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, aripiprazole demonstrated superior efficacy to placebo at week 3 and a maintenance of effect comparable to lithium or haloperidol at week 12. Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.</p><p>In a 6-week, placebo-controlled trial involving patients with a manic or mixed episode of Bipolar I Disorder, with or without psychotic features, who were partially non-responsive to lithium or valproate monotherapy for 2 weeks at therapeutic serum levels, the addition of aripiprazole as adjunctive therapy resulted in superior efficacy in reduction of manic symptoms than lithium or valproate monotherapy.</p><p>In a 26-week, placebo-controlled trial, followed by a 74-week extension, in manic patients who achieved remission on aripiprazole during a stabilization phase prior to randomisation, aripiprazole demonstrated superiority over placebo in preventing bipolar recurrence, primarily in preventing recurrence into mania but failed to demonstrate superiority over placebo in preventing recurrence into depression.</p><p>In a 52-week, placebo-controlled trial, in patients with a current manic or mixed episode of Bipolar I Disorder who achieved sustained remission (Y-MRS and MADRS total scores &le; 12) on aripiprazole (10 mg/day to 30 mg/day) adjunctive to lithium or valproate for 12 consecutive weeks, adjunctive aripiprazole demonstrated superiority over placebo with a 46 % decreased risk (hazard ratio of 0.54) in preventing bipolar recurrence and a 65 % decreased risk (hazard ratio of 0.35) in preventing recurrence into mania over adjunctive placebo but failed to demonstrate superiority over placebo in preventing recurrence into depression. Adjunctive aripiprazole demonstrated superiority over placebo on the secondary outcome measure, CGI-BP Severity of Illness score (mania). In this trial, patients were assigned by investigators with either open-label lithium or valproate monotherapy to determine partial non-response. Patients were stabilised for at least 12 consecutive weeks with the combination of aripiprazole and the same mood stabilizer. Stabilized patients were then randomised to continue the same mood stabilizer with double-blind aripiprazole or placebo. Four mood stabilizer subgroups were assessed in the randomised phase: aripiprazole + lithium; aripiprazole + valproate; placebo + lithium; placebo + valproate. The Kaplan-Meier rates for recurrence to any mood episode for the adjunctive treatment arm were 16 % in aripiprazole + lithium and 18 % in aripiprazole + valproate compared to 45 % in placebo + lithium and 19 % in placebo + valproate.</p><p><em><u>Paediatric population</u></em><em> </em></p><p><em>Schizophrenia in adolescents</em></p><p>In a 6-week placebo-controlled trial involving 302 schizophrenic adolescent patients (13-17 years), presenting with positive or negative symptoms, aripiprazole was associated with statistically significantly greater improvements in psychotic symptoms compared to placebo. In a sub-analysis of the adolescent patients between the ages of 15 to 17 years, representing 74 % of the total enrolled population, maintenance of effect was observed over the 26-week open-label extension trial.</p><p>In a 60- to 89-week, randomised, double-blind, placebo-controlled trial in adolescent subjects (n = 146; ages 13-17 years) with schizophrenia, there was a statistically significant difference in the rate of relapse of psychotic symptoms between the aripiprazole (19.39 %) and placebo (37.50 %) groups. The point estimate of the hazard ratio (HR) was 0.461 (95% confidence interval, 0.242-0.879) in the full population. In subgroup analyses the point estimate of the HR was 0.495 for subjects 13 to 14 years of age compared to 0.454 for subjects 15 to 17 years of age. However, the estimation of the HR for the younger (13-14 years) group was not precise, reflecting the smaller number of subjects in that group (aripiprazole, n = 29; placebo, n = 12), and the confidence interval for this estimation (ranging from 0.151 to 1.628) did not allow conclusions to be drawn on the presence of a treatment effect. In contrast the 95 % confidence interval for the HR in the older subgroup (aripiprazole, n = 69; placebo, n = 36) was 0.242 to 0.879 and hence a treatment effect could be concluded in the older patients.</p><p><em>Manic episodes in Bipolar I Disorder in children and adolescents</em></p><p>Aripiprazole was studied in a 30-week placebo-controlled trial involving 296 children and adolescents (10-17 years), who met DSM-IV criteria for Bipolar I Disorder with manic or mixed episodes with or without psychotic features and had a Y-MRS score &ge; 20 at baseline. Among the patients included in the primary efficacy analysis, 139 patients had a current co-morbid diagnosis of ADHD.</p><p>Aripiprazole was superior to placebo in change from baseline at week 4 and at week 12 on the Y-MRS total score. In a post-hoc analysis, the improvement over placebo was more pronounced in the patients with associated co-morbidity of ADHD compared to the group without ADHD, where there was no difference from placebo. Recurrence prevention was not established.</p><p>The most common treatment-emergent adverse events among patients receiving 30 mg were extrapyramidal disorder (28.3 %), somnolence (27.3 %), headache (23.2 %), and nausea (14.1 %). Mean weight gain in the 30 weeks treatment-interval was 2.9 kg as compared to 0.98 kg in patients treated with placebo.</p><p><em>Irritability associated with autistic disorder in paediatric patients (see section 4.2)</em></p><p>Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2-15 mg/day) and one fixed-dose (5, 10, or 15 mg/day)] and in one 52-week open-label trial. Dosing in these trials was initiated at 2 mg/day, increased to 5 mg/day after one week, and increased by 5 mg/day in weekly increments to the target dose. Over 75 % of patients were less than 13 years of age. Aripiprazole demonstrated statistically superior efficacy compared to placebo on the Aberrant Behaviour Checklist Irritability subscale. However, the clinical relevance of this finding has not been established. The safety profile included weight gain and changes in prolactin levels. The duration of the long-term safety study was limited to 52 weeks. In the pooled trials, the incidence of low serum prolactin levels in females (&lt; 3 ng/ml) and males (&lt; 2 ng/ml) in aripiprazole-treated patients was 27/46 (58.7 %) and 258/298 (86.6 %), respectively. In the placebo-controlled trials, the mean weight gain was 0.4 kg for placebo and 1.6 kg for aripiprazole.</p><p>Aripiprazole was also studied in a placebo-controlled, long-term maintenance trial. After a 13-26 week stabilisation on aripiprazole (2-15 mg/day) patients with a stable response were either maintained on aripiprazole or substituted to placebo for further 16 weeks. Kaplan-Meier relapse rates at week 16 were 35 % for aripiprazole and 52 % for placebo; the hazard ratio for relapse within 16 weeks (aripiprazole/placebo) was 0.57 (non-statistically significant difference). The mean weight gain over the stabilisation phase (up to 26 weeks) on aripiprazole was 3.2 kg, and a further mean increase of 2.2 kg for aripiprazole as compared to 0.6 kg for placebo was observed in the second phase (16 weeks) of the trial. Extrapyramidal symptoms were mainly reported during the stabilisation phase in 17 % of patients, with tremor accounting for 6.5 %.</p><p><em>Tics associated with Tourette&#39;s disorder in paediatric patients (see section 4.2)</em></p><p>The efficacy of aripiprazole was studied in paediatric subjects with Tourette&#39;s disorder (aripiprazole: n = 99, placebo: n = 44) in a randomised, double-blind, placebo controlled, 8 week study using a fixed dose weight-based treatment group design over the dose range of 5 mg/day to 20 mg/day and a starting dose of 2 mg. Patients were 7 - 17 years of age and presented an average score of 30 on Total Tic Score on the Yale Global Tic Severity Scale (TTS-YGTSS) at baseline. Aripiprazole showed an improvement on TTS-YGTSS change from baseline to week 8 of 13.35,for the low dose group (5 mg or 10 mg) and 16.94 for the high dose group (10 mg or 20 mg) as compared with an improvement of 7.09 in the placebo group.</p><p>The efficacy of aripiprazole in paediatric subjects with Tourette&#39;s syndrome (aripiprazole: n = 32, placebo: n = 29) was also evaluated over a flexible dose range of 2 mg/day to 20 mg/day and a starting dose of 2 mg, in a 10 week, randomised, double blind, placebo-controlled study conducted in South-Korea. Patients were 6 - 18 years and presented an average score of 29 on TTS-YGTSS at baseline. Aripiprazole group showed an improvement of 14.97 on TTS-YGTSS change from baseline to week 10 as compared with an improvement of 9.62 in the placebo group.</p><p>In both of these short term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning. No long term data are available with regard to the efficacy and the safety of aripiprazole in this fluctuating disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours after dosing. Aripiprazole undergoes minimal pre-systemic metabolism. The absolute oral bioavailability of the tablet formulation is 87 %. There is no effect of a high fat meal on the pharmacokinetics of aripiprazole.</p><p><u>Distribution</u></p><p>Aripiprazole is widely distributed throughout the body with an apparent volume of distribution of 4.9 l/kg, indicating extensive extravascular distribution. At therapeutic concentrations, aripiprazole and dehydro-aripiprazole are greater than 99 % bound to serum proteins, binding primarily to albumin.</p><p><u>Biotransformation</u></p><p>Aripiprazole is extensively metabolised by the liver primarily by three biotransformation pathways: dehydrogenation, hydroxylation, and N-dealkylation. Based on <em>in vitro</em> studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4. Aripiprazole is the predominant medicinal product moiety in systemic circulation. At steady state, dehydro-aripiprazole, the active metabolite, represents about 40 % of aripiprazole AUC in plasma.</p><p><u>Elimination</u></p><p>The mean elimination half-lives for aripiprazole are approximately 75 hours in extensive metabolisers of CYP2D6 and approximately 146 hours in poor metabolisers of CYP2D6.</p><p>The total body clearance of aripiprazole is 0.7 ml/min/kg, which is primarily hepatic.</p><p>Following a single oral dose of [<sup>14</sup>C]-labelled aripiprazole, approximately 27 % of the administered radioactivity was recovered in the urine and approximately 60 % in the faeces. Less than 1 % of unchanged aripiprazole was excreted in the urine and approximately 18 % was recovered unchanged in the faeces.</p><p><u>Paediatric population</u></p><p>The pharmacokinetics of aripiprazole and dehydro-aripiprazole in paediatric patients 10 to 17 years of age were similar to those in adults after correcting for the differences in body weights.</p><p><strong><u>Pharmacokinetics in special patient groups</u></strong><strong> </strong></p><p><em>Elderly</em></p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy elderly and younger adult subjects, nor is there any detectable effect of age in a population pharmacokinetic analysis in schizophrenic patients.</p><p><em>Gender</em></p><p>There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.</p><p><em>Smoking</em></p><p>Population pharmacokinetic evaluation has revealed no evidence of clinically significant effects from smoking on the pharmacokinetics of aripiprazole.</p><p><em>Race</em></p><p>Population pharmacokinetic evaluation showed no evidence of race-related differences on the pharmacokinetics of aripiprazole.</p><p><em>Renal impairment</em></p><p>The pharmacokinetic characteristics of aripiprazole and dehydro-aripiprazole were found to be similar in patients with severe renal disease compared to young healthy subjects.</p><p><em>Hepatic impairment</em></p><p>A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and C) did not reveal a significant effect of hepatic impairment on the pharmacokinetics of aripiprazole and dehydro-aripiprazole, but the study included only 3 patients with Class C liver cirrhosis, which is insufficient to draw conclusions on their metabolic capacity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p><p>Toxicologically significant effects were observed only at doses or exposures that were sufficiently in excess of the maximum human dose or exposure, indicating that these effects were limited or of no relevance to clinical use. These included: dose-dependent adrenocortical toxicity (lipofuscin pigment accumulation and/or parenchymal cell loss) in rats after 104 weeks at 20 to 60 mg/kg/day (3 to 10 times the mean steady-state AUC at the maximum recommended human dose) and increased adrenocortical carcinomas and combined adrenocortical adenomas/carcinomas in female rats at 60 mg/kg/day (10 times the mean steady-state AUC at the maximum recommended human dose). The highest nontumorigenic exposure in female rats was 7 times the human exposure at the recommended dose.</p><p>An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/kg/day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/m<sup>2</sup>). However, the concentrations of the sulphate conjugates of hydroxy aripiprazole in human bile at the highest dose proposed, 30 mg per day, were no more than 6 % of the bile concentrations found in the monkeys in the 39-week study and are well below (6 %) their limits of <em>in vitro</em> solubility.</p><p>In repeat-dose studies in juvenile rats and dogs, the toxicity profile of aripiprazole was comparable to that observed in adult animals, and there was no evidence of neurotoxicity or adverse reactions on development.</p><p>Based on results of a full range of standard genotoxicity tests, aripiprazole was considered non-genotoxic. Aripiprazole did not impair fertility in reproductive toxicity studies. Developmental toxicity, including dose-dependent delayed foetal ossification and possible teratogenic effects, were observed in rats at doses resulting in subtherapeutic exposures (based on AUC) and in rabbits at doses resulting in exposures 3 and 11 times the mean steady-state AUC at the maximum recommended clinical dose. Maternal toxicity occurred at doses similar to those eliciting developmental toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Maize starch</p><p>Microcrystalline cellulose</p><p>Hydroxypropyl cellulose</p><p>Magnesium stearate</p><p>Red iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at room temperature below 30&deg;C and in its package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu blister</p><p>28 tablets packages</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MN Pharmaceuticals (Mustafa Nevzat İlaç Sanayii A.Ş.)
Prof. Dr. Bülent Tarcan Sok., Pak İş Merkezi No: 5/1
34349 Gayrettepe/İstanbul
Phone	: 0 (212) 337 38 00 
Fax	: 0 (212) 337 38 01

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>